Five-year trial of deferiprone chelation therapy in thalassaemia major patients

Acta Haematologica

Volumn 112, Issue 4, 2004, Pages 179-183

  Taher, A ^a,b   Aoun, E ^a   Sharara, A I ^a   Mourad, F ^a   Gharzuddine, W ^a   Koussa, S ^b   Inati, A ^b   Dhillon, A P ^c   Hoffbrand, A V ^c,d  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Chronic Care Center Hazmieh   (Lebanon)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Deferiprone; Echocardiography; Iron chelation; Liver biopsy; Thalassemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEFERIPRONE; FERRITIN; HEPATITIS C ANTIBODY; IRON; MESSENGER RNA; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRY WEIGHT; FEMALE; FERRITIN BLOOD LEVEL; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IRON CHELATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER WEIGHT; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THALASSEMIA MAJOR;

EID: 9144230310     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081268     Document Type: Article

References (18)

1. Porter JB: Practical management of iron overload. Br J Haematol 2001;115:239-252.
2. Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta Haematol 1996;95:26-36.
3. Hoffbrand AV, Cohen A, Hershko C: Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003;102:17-24.
4. Anderson L, Wonke B, Prescott E, Holden S, Walaker JM, Pennell DJ: Comparison of the effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360:516-520.
5. Piga A, Gaglioti C, Fogliacco E, Tricta F: Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis. Haematologica 2003;88:489-496.
6. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McCelland RA, Burt AD, Fleming KA: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417-423.
7. Barman Balfour JA, Foster RH: Deferiprone: A review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999;58:553-578.
8. Wanless IR, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen A: Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566-1569.
9. Taher A, Chamoun FM, Koussa S, Abi Saad M, Khoriaty AI, Neeman R, Mourad FH: Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine. Acta Haematol 1999;101:173-177.
10. Ishak K, Baptista A, Bianchi L, Callea F, De-Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
11. Barry M, Sherlock S: Measurement of liver iron content in liver biopsy specimens. Lancet 1971;i:100-103.
12. Scheuer PJ, Lefkowitch JH: Liver Biopsy Interpretation, ed 6. London, Saunders, 2000, p 274.
13. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573.
14. Olivieri NF, Brittenham GM: Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
15. Gharzuddine WS, Kazma HK, Nuwayhid IA, Bitar FF, Koussa SF, Moukarbel GV, Taher A: Doppler characterization of left ventricular diastolic function in beta-thalassaemia major. Evidence for an early stage of impaired relaxation. Eur J Echocardiogr 2002;1:47-51.
16. Tondury P, Zimmermann A, Nielsen P, Hirt A: Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998;101:413-415.
17. Wonke B, Wright C, Hoffbrand AV: Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103:361-364.
18. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A: Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003;121:187-189.